SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001193125-23-233465 from Neumora Therapeutics, Inc. (NMRA) (CIK 0001885522) (NMRA)

Neumora Therapeutics, Inc. (NMRA) (CIK 0001885522)
Date: Sept. 12, 2023 · CIK: 0001885522 · Accession: 0001193125-23-233465

AI Filing Summary & Sentiment

File numbers found in text: 333-274229

Date
September 12, 2023
Author
J.P. MORGAN SECURITIES LLC
Form
CORRESP
Company
Neumora Therapeutics, Inc. (NMRA) (CIK 0001885522)

Letter

Re: Neumora Therapeutics, Inc. (the “Registrant”)

September 12, 2023

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

Attention: Daniel Crawford

Registration Statement on Form S-1 (File No. 333-274229)

Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended, we wish to advise that between September 11, 2023 and the date hereof, approximately 1,210 copies of the Preliminary Prospectus, dated September 11, 2023, were distributed to prospective underwriters, institutional investors and prospective dealers in connection with the above-captioned Registration Statement, as amended.

We wish to advise you that the participating underwriters have informed us that they have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

We hereby join in the request of the Registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 4:00 p.m. Eastern Time, on Thursday, September 14, 2023 or as soon thereafter as practicable.

[signature page follows]

Very truly yours,
J.P. MORGAN SECURITIES LLC

Show Raw Text
CORRESP
1
filename1.htm

CORRESP

 September 12, 2023

United States Securities and Exchange Commission

 Division of
Corporation Finance

 100 F Street, N.E.

 Washington, DC 20549

 Attention:     Daniel Crawford

Re:
 Neumora Therapeutics, Inc. (the “Registrant”)

Registration Statement on Form S-1 (File
No. 333-274229)

 Request for Acceleration

Ladies and Gentlemen:

 Pursuant to Rule 460 of the General
Rules and Regulations under the Securities Act of 1933, as amended, we wish to advise that between September 11, 2023 and the date hereof, approximately 1,210 copies of the Preliminary Prospectus, dated September 11, 2023, were
distributed to prospective underwriters, institutional investors and prospective dealers in connection with the above-captioned Registration Statement, as amended.

We wish to advise you that the participating underwriters have informed us that they have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

 We hereby join in the request of the Registrant that the
effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 4:00 p.m. Eastern Time, on Thursday, September 14, 2023 or as soon thereafter as practicable.

[signature page follows]

Very truly yours,

J.P. MORGAN SECURITIES LLC

BOFA SECURITIES, INC.

As representatives of the Underwriters

J.P. MORGAN SECURITIES LLC

By:

 /s/ Benjamin H. Burdett

Name: Benjamin H. Burdett

Title: Managing Director

BOFA SECURITIES, INC.

By:

 /s/ Michael Liloia

Name: Michael Liloia

Title: Director

 [Signature Page to Acceleration Request Letter]